GLOW blend protocols in the published literature

How much GLOW peptide should be injected?

review

No study among the research behind this page has given GHK-Cu, BPC-157 and TB-500 together to anybody, in any amount, so there is no combination dosing study to report.7 That is the whole answer to the question as asked, and everything below is an account of what sits around the gap. GLOW (GHK-Cu + BPC-157 + TB-500) is three separate research compounds sharing one vial. Each has its own small and uneven record, and those records were built one compound at a time. A 2026 orthopaedic review covering all three states that information regarding the indications, dosing, frequency, and duration of treatment remains unknown.5 Adding three published protocols together would certainly produce a figure, and the figure would be an invention. No study among the research behind this page has measured what these compounds do to one another, at what proportion, or at what interval. Three partial records do not combine into a schedule for a mixture, any more than three separate recipes combine into a meal. What each separate record describes is what one compound did on its own, which does not tell anybody what three of them do at once.

What is on a GLOW peptide dosage chart?

animal model

Charts circulating under this name set out a weekly amount in milligrams, a number of injections and a cycle length, laid out as though the sequence came from somewhere. The published literature contains no such sequence for this combination. What the literature does contain, for two of the three compounds, is a single animal experiment with its numbers printed. Thirty-two male Sprague-Dawley rats were randomly assigned to four groups, with eight rats in each group: control, BPC-157 (10 µg/kg/day), TB-500 (60 µg/kg/day), and combined BPC-157 + TB-500.1 Those treatments were administered intraperitoneally for four weeks postoperatively, which means injected into the abdominal cavity after surgery.1 A chart honest to that record would have one row, and the row would say rat. The third compound in the blend does not appear in it at all, and neither does anything in milligrams per week.

What do 70 mg and the 50/10/10 split on the label mean?

animal model

Those numbers describe the contents of the container rather than anything anybody has investigated. Where a vial is labelled with three figures that sum to 70, the figures are milligram quantities of each of the three compounds, and the largest share is normally the copper peptide. That is arithmetic about packaging, and it is independently checkable. What it is not is a ratio anybody arrived at by experiment. No study among the research behind this page has tested one proportion of these three against another, in people or in animals, so there is no basis in the literature for 50/10/10 or for any other split. The one experiment that paired two of them used nothing like that balance. It gave BPC-157 (10 µg/kg/day) and TB-500 (60 µg/kg/day), which is six times as much of the second compound as the first, and the authors describe their own work as preliminary findings pending dose-optimization and longer-term studies.1

How much GLOW peptide per day?

animal model

Daily is the frequency the only relevant experiment used, and it used it in rats. In that study BPC-157 was given at 10 µg/kg/day and TB-500 at 60 µg/kg/day, every day for four weeks after tendon surgery.1 Both of those figures are expressed per kilogram of the animal's body weight. The rats each weighed approximately 330 g, so the quantities involved are small fractions of a milligram, and scaling them up to a person by body weight is not a validated step for any of these compounds.1 We do not publish that sum. For people, there is nothing daily to report. A 2025 narrative review notes that only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety, and none of the three was designed to find an amount rather than to look for an effect.4

Has anyone studied the three compounds given together?

animal model

No study among the research behind this page has given GHK-Cu, BPC-157 and TB-500 together to anybody, in any amount, so there is no combination dosing study to report.7 Two of the three have been given together once, to rats, and the result is worth reading closely. That experiment ran four arms: a control group, BPC-157 alone, TB-500 alone, and the two combined. Biomechanical testing revealed higher maximum load to failure values in the BPC-157 and TB-500 groups compared to controls, and the combined arm produced no added benefit.1 The authors offer an explanation and flag it as unproven, writing that the absence of additive effects with combination therapy may reflect convergence on shared downstream pathways.1 Read carefully what that does and does not establish. It is a single rat experiment, covering two compounds, assessed at four weeks, and its combination arm did not outperform either single-compound arm. That is not evidence that combining these compounds is pointless, and it is certainly not evidence that combining them contributes anything.

What amounts has BPC-157 been given in?

systematic review

BPC-157 (body protection compound 157) has the fullest numeric record of the three, and all of it is in animals. The 2026 tendon experiment gave BPC-157 (10 µg/kg/day) by injection into the abdominal cavity for four weeks.1 The older and considerably more cited experiment investigated a range rather than establishing a number. In the 2003 rat Achilles study, agents were given per kilogram of body weight, once daily, and the doses compared were 10 microg, 10 ng or 10 pg of BPC 157 against saline.2 Those three levels span a millionfold, which is the shape of a dose-response experiment and not a working figure. In people there is no documented amount whatsoever. A 2025 systematic review found 36 studies, 35 of them preclinical, and reported that no clinical safety data were found.3 What is published about BPC-157 in humans describes the anatomical location of the injection rather than the quantity administered into it.

What amounts has TB-500 been given in?

registered trial

TB-500 (a synthetic fragment of thymosin beta 4) carries one printed animal figure and no published human one. In the rat tendon experiment it was given at TB-500 (60 µg/kg/day) into the abdominal cavity, daily, for four weeks after surgery.1 That is six times the per-kilogram amount of BPC-157 in the same study, which is a useful corrective to the idea that these compounds are interchangeable units of the same thing. The human record is registrations rather than results. A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers and A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers are both listed as COMPLETED, and neither has published an amount.1415 A 2026 orthopaedic review puts the position plainly: TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking.5

What amounts has GHK-Cu been given in?

review

GHK-Cu (copper tripeptide-1) is usually the largest share of a blended vial and it has the weakest dosing record of the three. It does not appear in the rat tendon experiment at all, so the one combination study on file says nothing about it. Its own problem runs deeper than a missing number, because the compound carries a metal. A 2026 evidence-mapping review found that across delivery studies, molar occupancy, labile copper, and release of intact GHK-Cu versus apo-GHK/free copper are usually not resolved.8 Labile copper means copper sitting loose rather than bound into the peptide. So an amount in milligrams does not settle how much of anything a preparation actually delivers. The same review notes that a 13-participant post-CO2-laser study was negative on objective endpoints, and a 2026 orthopaedic primer adds that no clinical data support its use for musculoskeletal conditions.85

How were these compounds administered in the studies?

systematic review

Three routes appear in the published record, and none of them is the one most people mean by an injection of a blend. The rat work used the abdominal cavity, giving the compounds intraperitoneally for four weeks postoperatively.1 The human BPC-157 work went into a joint. A retrospective study describes intraarticular injection of BPC-157 for unspecified chronic knee pain, in which 7 of 12 patients reported relief for >6 months, with no amount recorded.3 The same chart review is also the closest thing to a human combination: the other 4 patients received a combination of 2 peptide injections of BPC 157 and TB4.9 Four people, two compounds, a telephone follow-up months later and no quantities written down. That is the entire human record for giving any two of these together, and it tells you the route rather than the dose.

How long can GLOW peptide be taken for?

human pilot / early trial

Nothing among the research behind this page establishes a duration, because nothing in the published record administered the blend at all. The longest documented course of any two of these compounds together is four weeks, in rats, following an operation.1 The human intervals that exist are observation periods rather than courses of administration. In the knee chart review, of the 17 patients in the study, 16 were contacted by phone to follow up on the status of their knee pain, with most having been injected six months to a year beforehand.9 Nobody documented what happened in the interval between the injection and the telephone call. So the duration question is being asked of a literature that has not approached it. The honest shape of the answer is that four weeks is the longest anyone has administered two of these compounds in an animal, and that no human course of any length has been published for the combination.

Is there a cycle, a break or a taper for GLOW?

animal model

No study among the research behind this page has tested a break, a taper or a repeat course for any of the three compounds, alone or combined. In the research behind this page, there is no interval to report because the question has not been put to an experiment. What the record holds instead is one continuous block of daily dosing in rats, running four weeks and stopping when the animals were assessed.1 The schedule ended because the study ended, which is a fact about the design rather than a finding about the compound. A 2026 review of peptides in ageing names the gap directly. Significant knowledge gaps include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy.7 All three of those gaps bear directly on cycling, and all three remain open. No study among the research behind this page has published what happens after a course concludes, so there is no rebound, no persistence and no tolerance available to describe in either direction.

How much bacteriostatic water goes into a 70 mg blended vial?

The arithmetic operates exactly as it does for a single compound, with one complication that matters. A vial labelled 70 mg contains 70,000 micrograms of material altogether, so 2 mL of bacteriostatic water produces a concentration of 35,000 mcg/mL and 5 mL produces 14,000 mcg/mL. The complication is that any such concentration describes the mixture rather than any individual compound within it. Where a label divides 70 mg into 50, 10 and 10, a 5 mL reconstitution delivers 10,000 mcg/mL of the first compound and 2,000 mcg/mL of each of the remaining two into the same millilitre. A single mark on a U-100 insulin syringe, one hundredth of a millilitre, therefore carries three different quantities simultaneously. Nothing among the research behind this page establishes what those three quantities ought to be. The conversions are exact and the target is absent, and the absence is the half of that sentence which decides everything.

Why do the circulating numbers vary so much?

human pilot / early trial

Because they are not anchored to anything. Where numbers do exist for these compounds one at a time, they differ by design rather than by disagreement. A 2026 scoping review of six peptides notes that significant heterogeneity existed in dosing and route of administration.6 In a body of research, that kind of spread means studies asking different questions in different animals. In a chart passed around online it means something else, because those figures were never produced by a study at all. The root of it is the same either way. No regulator has approved any of the three at any amount, so there is no fixed point for a number to be near or far from. A 2026 review covering all three states that information regarding the indications, dosing, frequency, and duration of treatment remains unknown.5 Until someone gives the three together and measures what happens, the spread in the charts is a spread between guesses rather than between findings.